David A. Siegel Legend Biotech Corp Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Legend Biotech Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 504,100 shares of LEGN stock, worth $19 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

504,100

Previous 327,400 53.97%

Holding current value

$19 Million

Previous $10.7 Million 60.56%

% of portfolio

0.04%

Previous 0.03%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$31.43 - $39.7 $5.55 Million - $7.01 Million	176,700 Added 53.97%	504,100 $17.1 Million
Q4 2024 Feb 14, 2025	BUY	$32.49 - $50.28 $9.58 Million - $14.8 Million	294,800 Added 904.29%	327,400 $10.7 Million
Q3 2024 Nov 14, 2024	BUY	$43.55 - $59.88 $1.42 Million - $1.95 Million	32,600 New	32,600 $1.59 Million
Q4 2023 Feb 14, 2024	SELL	$57.25 - $69.74 $4.93 Million - $6 Million	-86,100 Reduced 85.67%	14,400 $866,000
Q3 2023 Nov 14, 2023	BUY	$63.16 - $76.5 $6.35 Million - $7.69 Million	100,500 New	100,500 $6.75 Million
Q2 2022 Aug 15, 2022	SELL	$33.54 - $55.0 $1.19 Million - $1.96 Million	-35,600 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$31.02 - $48.18 $936,804 - $1.46 Million	30,200 Added 559.26%	35,600 $1.29 Million
Q4 2021 Feb 14, 2022	BUY	$41.14 - $56.98 $222,156 - $307,692	5,400 New	5,400 $252,000
Q3 2021 Nov 15, 2021	SELL	$35.31 - $50.56 $296,604 - $424,704	-8,400 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$25.8 - $41.09 $216,720 - $345,156	8,400 New	8,400 $345,000

Others Institutions Holding LEGN

# of Institutions

229

Shares Held

74.4M

Call Options Held

247K

Put Options Held

406K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $6.3B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account